Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer von Lücking, Ulrich, Scholz, Arne, Lienau, Philip, Siemeister, Gerhard, Kosemund, Dirk, Bohlmann, Rolf, Briem, Hans, Terebesi, Ildiko, Meyer, Kirstin, Prelle, Katja, Denner, Karsten, Bömer, Ulf, Schäfer, Martina, Eis, Knut, Valencia, Ray, Ince, Stuart, von Nussbaum, Franz, Mumberg, Dominik, Ziegelbauer, Karl, Klebl, Bert, Choidas, Axel, Nussbaumer, Peter, Baumann, Matthias, Schultz‐Fademrecht, Carsten, Rühter, Gerd, Eickhoff, Jan, Brands, Michael

Volltext

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in pr... von Scholz, Arne, Oellerich, Thomas, Hussain, Akhtar, Lindner, Sarah, Luecking, Ulrich, Walter, Annette O., Ellinghaus, Peter, Valencia, Ray, von Nussbaum, Franz, Mumberg, Dominik, Brands, Michael, Ince, Stuart, Serve, Hubert, Ziegelbauer, Karl

Volltext

1,2-Diacetals:  A New Opportunity for Organic Synthesis von Ley, Steven V, Baeschlin, Daniel K, Dixon, Darren J, Foster, Alison C, Ince, Stuart J, Priepke, Henning W. M, Reynolds, Dominic J

Volltext

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer von Lücking, Ulrich, Kosemund, Dirk, Böhnke, Niels, Lienau, Philip, Siemeister, Gerhard, Denner, Karsten, Bohlmann, Rolf, Briem, Hans, Terebesi, Ildiko, Bömer, Ulf, Schäfer, Martina, Ince, Stuart, Mumberg, Dominik, Scholz, Arne, Izumi, Raquel, Hwang, Stuart, von Nussbaum, Franz

Volltext

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models von Grünewald, Sylvia, Politz, Oliver, Bender, Sebastian, Héroult, Mélanie, Lustig, Klemens, Thuss, Uwe, Kneip, Christoph, Kopitz, Charlotte, Zopf, Dieter, Collin, Marie‐Pierre, Boemer, Ulf, Ince, Stuart, Ellinghaus, Peter, Mumberg, Dominik, Hess‐Stumpp, Holger, Ziegelbauer, Karl

Volltext

Chiral Dihydroxyacetone Equivalents in Synthesis: An Expedient Diastereo- and Enantioselective Synthesis of Differentially Protected Ketopolyols von Enders, Dieter, Ince, Stuart J.

Volltext

Rapid assembly of oligosaccharides: 1,2-diacetal-mediated reactivity tuning in the coupling of glycosyl fluorides von Baeschlin, Daniel K, Green, Luke G, Hahn, Michael G, Hinzen, Berthold, Ince, Stuart J, Ley, Steven V

Volltext

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models von Politz, Oliver, Siegel, Franziska, Bärfacker, Lars, Bömer, Ulf, Hägebarth, Andrea, Scott, William J., Michels, Martin, Ince, Stuart, Neuhaus, Roland, Meyer, Kirstin, Fernández‐Montalván, Amaury Ernesto, Liu, Ningshu, von Nussbaum, Franz, Mumberg, Dominik, Ziegelbauer, Karl

Volltext

Abstract A099: Safety, tolerability, pharmacokinetics, and efficacy of pan-fibroblast growth factor receptor inhibitor rogaratinib in Japanese patients with refractory, locally adv... von Tahara, Makoto, Takahashi, Shunji, Ocker, Matthias, Ince, Stuart, Nogai, Hendrik, Zhang, Changliang, Sei, Fumiyoshi, Ellinghaus, Peter

Volltext

Abstract 3738: Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877 von Ellinghaus, Peter, Ocker, Matthias, Bender, Sebastian, Kneip, Christoph, Ince, Stuart, Joerger, Markus, Schuler, Martin

Volltext

Preparation and Reactions of 2,2-Dimethyl-1,3-dioxan-5-one-SAMP-Hydrazone: A Versatile Chiral Dihydroxyacetone Equivalent von Enders, Dieter, Voith, Matthias, Ince, Stuart J.

Volltext

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia von Byrne, Michael, Frattini, Mark G., Ottmann, Oliver G., Mantzaris, Ioannis, Wermke, Martin, Lee, Daniel J., Morillo, Daniel, Scholz, Arne, Ince, Stuart, Valencia, Ray, Souza, Fabricio, Cordoba, Raul

Volltext

Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical a... von Diamond, Jennifer Robinson, Moreno, Victor, Lim, Emerson A., Cordoba, Raul, Cai, Charles, Ince, Stuart James, Lettieri, John T., Merz, Claudia, Valencia, Ray, Boni, Valentina

Volltext

Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin von Héroult, Mélanie, Ocker, Matthias, Kopitz, Charlotte, Zopf, Dieter, Hägebarth, Andrea, Ziegelbauer, Karl, Ince, Stuart, Ellinghaus, Peter

Volltext

Abstract 379: Allosteric AKT1/2-inhibitor BAY 1125976 as potent inhibitor in luminal breast cancer resistant to antihormone therapy von Politz, Oliver, Baerfacker, Lars, Ince, Stuart, Haegebarth, Andrea, Liu, Ningshu, Neuhaus, Roland, Boemer, Ulf, Michels, Martin, Ziegelbauer, Karl, Mumberg, Dominik

Volltext

Patient selection using novel RNA-based approaches: Early experience from a phase I study with the pan-FGFR inhibitor BAY 1163877 in patients with urothelial bladder cancer von Joerger, Markus, Schuler, Martin H., Cassier, Philippe Alexandre, Hildebrandt, Sandra, Behre, Simone, Helmbrecht, Corinna, Kerpen, Stephanie, Zielinski, Dirk, Ince, Stuart, Ocker, Matthias, Ellinghaus, Peter

Volltext

Kinase Data Mining: Dealing with the Information (Over-)Flow von Eis, Knut, Ince, Stuart J, Jahn, Carsten, Jautelat, Rolf, Katchourovsky, Vladimir, Kettschau, Georg, Woloszczak, Rolf

Volltext

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops von Luecking, Ulrich T., Scholz, Arne, Kosemund, Dirk, Bohlmann, Rolf, Briem, Hans, Lienau, Philip, Siemeister, Gerhard, Terebesi, Ildiko, Meyer, Kirstin, Prelle, Katja, Valencia, Ray, Ince, Stuart, Nussbaum, Franz von, Mumberg, Dominik, Ziegelbauer, Karl, Brands, Michael

Volltext

Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers von Politz, Oliver, Scholz, Arne, Haegebarth, Andrea, Liu, Ningshu, Baerfacker, Lars, Ince, Stuart, Neuhaus, Roland, Boemer, Ulf, Michels, Martin, Mumberg, Dominik

Volltext

Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti... von Scholz, Arne, Luecking, Ulrich, Siemeister, Gerhard, Lienau, Philip, Boemer, Ulf, Ellinghaus, Peter, Walter, Annette O., Valencia, Ray, Ince, Stuart, von Nussbaum, Franz, Mumberg, Dominik, Brands, Michael, Ziegelbauer, Karl

Volltext